公开(公告)号：WO2013017573A1

公开(公告)日：2013-02-07

申请号：PCT/EP2012/064904

申请日：2012-07-30

Applicant: MIACOM DIAGNOSTICS GMBH ,  STANGE, Mirko ,  STEIN, FREIHERR VON, Walter

Inventor： STANGE, Mirko ,  STEIN, FREIHERR VON, Walter

IPC: C12Q1/68 ,  C12Q1/18

CPC classification number: C12Q1/18 ,  C12Q1/34 ,  G01N2333/31 ,  G01N2333/936 ,  G01N2415/00

Abstract: The invention relates to a method for detecting a resistance of at least one cell of a microorganism to at least one antibiotic substance. More specifically, the invention concerns a method for detection of resistance of pathogen bacteria to β-lactam antibiotics. According to the invention a patient's probe is treated with at least one disrupting agent that at least partially damages the cell wall of the microorganism. The concentration of the disrupting agent needed to detectably damage the cell is a measure for the sensitivity of the cell to the antibiotic substance. Surprisingly, it turned out that the cell wall of resistant strains is weakened so that treatment with a disrupting agent in low concentrations results in partial cell wall destruction. Due to cell wall destruction, marker substances can easily enter the cells so that they can be detected by standard methods. This effect is not observed with strains that are sensitive to the antibiotic so that, depending on the concentration of the disrupting agent, a clear distinction between resistant and sensitive cells can be accomplished.

Abstract translation: 本发明涉及一种用于检测至少一种微生物细胞对至少一种抗生素物质的抗性的方法。 更具体地，本发明涉及用于检测病原体细菌对β-内酰胺抗生素的抗性的方法。 根据本发明，用至少一种至少部分损伤微生物细胞壁的破坏剂处理患者的探针。 可检测地损伤细胞所需的破坏剂的浓度是细胞对抗生素物质的敏感性的量度。 令人惊讶的是，证明抗性菌株的细胞壁被削弱，使得用低浓度的破坏剂处理导致部分细胞壁破坏。 由于细胞壁破坏，标记物质可以容易地进入细胞，以便通过标准方法检测。 对抗生素敏感的菌株没有观察到这种效果，因此根据破坏剂的浓度，可以实现抗性和敏感细胞之间的明确区别。

公开(公告)号：WO2009143168A3

公开(公告)日：2010-01-21

申请号：PCT/US2009044539

申请日：2009-05-19

Applicant: NOVARTIS AG ,  DONNELLY JOHN ,  WU PING ,  SANTOS GEORGE ,  GIULIANI MARZIA MONICA ,  ANDREWS WILLIAM ,  CHEN JIE

Inventor： DONNELLY JOHN ,  WU PING ,  SANTOS GEORGE ,  GIULIANI MARZIA MONICA ,  ANDREWS WILLIAM ,  CHEN JIE

IPC: G01N33/53 ,  A61K39/00 ,  A61K39/095 ,  G01N33/569

CPC classification number: G01N33/569 ,  G01N33/53 ,  G01N2333/205 ,  G01N2333/22 ,  G01N2333/245 ,  G01N2333/285 ,  G01N2333/31 ,  G01N2333/315

Abstract: The present invention is directed to methods, assays and compositions for implementing such methods and assays for assessing efficacy of individual components in multi-component vaccines and for assessing efficacy of a vaccine against a pathogen. In one aspect, the method of assessing efficacy of a vaccine against a pathogen is a quick assay that tests for an activity correlated with efficacy such as binding in an ELISA rather than requiring the time and expense of an assay that detects actual bactericidal activity. In another aspect, the method for testing the efficacy of an individual component in a multi-component vaccine includes obtaining an immune sample from a subject inoculated with the multi-component vaccine; blocking the portion of the immune sample that recognizes the individual component such as by addition of the individual component, and testing the efficacy of the immune sample to respond to the pathogen.

Abstract translation: 本发明涉及用于实施用于评估多组分疫苗中各个组分的功效并用于评估针对病原体的疫苗的功效的这些方法和测定的方法，测定和组合物。 在一个方面，评估疫苗针对病原体的功效的方法是测试与功效相关的活性的快速测定，例如在ELISA中的结合，而不是需要检测实际杀菌活性的测定的时间和费用。 另一方面，用于测试多组分疫苗中单个组分的功效的方法包括从接种多组分疫苗的受试者获得免疫样品; 阻止识别个体成分的免疫样品的部分，例如通过加入各个组分，以及测试免疫样品对病原体的反应的功效。

公开(公告)号：WO2009143168A2

公开(公告)日：2009-11-26

申请号：PCT/US2009/044539

申请日：2009-05-19

Applicant: NOVARTIS AG ,  DONNELLY, John ,  WU, Ping ,  SANTOS, George ,  GIULIANI, Marzia, Monica ,  ANDREWS, William ,  CHEN, Jie

Inventor： DONNELLY, John ,  WU, Ping ,  SANTOS, George ,  GIULIANI, Marzia, Monica ,  ANDREWS, William ,  CHEN, Jie

IPC: G01N33/53 ,  G01N33/569 ,  A61K39/00 ,  A61K39/095

CPC classification number: G01N33/569 ,  G01N33/53 ,  G01N2333/205 ,  G01N2333/22 ,  G01N2333/245 ,  G01N2333/285 ,  G01N2333/31 ,  G01N2333/315

Abstract: The present invention is directed to methods, assays and compositions for implementing such methods and assays for assessing efficacy of individual components in multi-component vaccines and for assessing efficacy of a vaccine against a pathogen. In one aspect, the method of assessing efficacy of a vaccine against a pathogen is a quick assay that tests for an activity correlated with efficacy such as binding in an ELISA rather than requiring the time and expense of an assay that detects actual bactericidal activity. In another aspect, the method for testing the efficacy of an individual component in a multi-component vaccine includes obtaining an immune sample from a subject inoculated with the multi-component vaccine; blocking the portion of the immune sample that recognizes the individual component such as by addition of the individual component, and testing the efficacy of the immune sample to respond to the pathogen.

Abstract translation: 本发明涉及用于实施用于评估多组分疫苗中各个组分的功效并用于评估针对病原体的疫苗的功效的这些方法和测定的方法，测定和组合物。 在一个方面，评估疫苗针对病原体的功效的方法是测试与功效相关的活性的快速测定，例如在ELISA中的结合，而不是需要检测实际杀菌活性的测定的时间和费用。 另一方面，用于测试多组分疫苗中单个组分的功效的方法包括从接种多组分疫苗的受试者获得免疫样品; 阻止识别个体成分的免疫样品的部分，例如通过加入各个组分，以及测试免疫样品对病原体的反应的功效。

公开(公告)号：WO2009080811A1

公开(公告)日：2009-07-02

申请号：PCT/EP2008/068168

申请日：2008-12-22

Applicant: AFFIBODY AB ,  ABRAHMSÉN, Lars ,  HERNE, Nina ,  LENDEL, Christofer ,  FELDWISCH, Joachim

Inventor： ABRAHMSÉN, Lars ,  HERNE, Nina ,  LENDEL, Christofer ,  FELDWISCH, Joachim

IPC: C07K1/04 ,  C12N15/10 ,  G01N33/68 ,  C12Q1/68

CPC classification number: C07K14/31 ,  C07K1/047 ,  C12N15/1037 ,  C12N15/1041 ,  C12N15/1044 ,  C12N15/1075 ,  C40B40/10 ,  G01N33/6845 ,  G01N2333/31

Abstract: Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q, wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling. Furthermore, methods for selecting a desired polypeptide having an affinity for a predetermined target from a population of polypeptides, isolation of a polynucleotide encoding a desired polypeptide having an affinity for a predetermined target, identifying a desired polypeptide having an affinity for a predetermined target, selecting and identifying a desired polypeptide having affinity for a predetermined target, and production of a desired polypeptide having an affinity for a predetermined target are disclosed.

Abstract translation: 基于常见支架的多肽变体群体，群体中的每个多肽包含支架氨基酸序列EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ或AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q，其中每个X分别对应于在群体中变化的氨基酸残基 被披露。 还公开了多核苷酸的种群，其中每个成员编码多肽群体的成员。 此外，公开了这样的多肽群体和这种多核苷酸群体的组合，其中多肽群体的每个成员通过用于基因型 - 表型偶联的方法与编码该成员的多核苷酸物理或空间相关联。 此外，从多肽群体中选择对预定靶标具有亲和性的期望多肽的方法，分离编码对预定靶标具有亲和性的期望多肽的多核苷酸，鉴定对预定靶标具有亲和性的期望多肽，选择 并鉴定对预定靶标具有亲和力的所需多肽，以及对预定靶标具有亲和性的所需多肽的制备。

公开(公告)号：WO2009071831A1

公开(公告)日：2009-06-11

申请号：PCT/FR2008/052119

申请日：2008-11-25

Applicant: BIOMÉRIEUX ,  HALIMI, Diane ,  ORENGA, Sylvain ,  PERRY, John

Inventor： HALIMI, Diane ,  ORENGA, Sylvain ,  PERRY, John

IPC: C12Q1/04 ,  G01N33/569

CPC classification number: C12Q1/04 ,  C12Q1/045 ,  G01N33/56938 ,  G01N2333/31

Abstract: L'invention concerne un milieu réactionnel pour la caractérisation de Staphylococcus aureus comprenant un indicateur métabolique qui est un substrat de beta ribosidase en combinaison avec au moins un autre indicateur métabolique et/ou au moins un régulateur métabolique. L'invention concerne également un procédé de détection et/ou d'identification de Staphylococcus aureus , caractérisé en ce qu'il comprend les étapes suivantes : a) disposer d'un milieu réactionnel comprenant un indicateur métabolique qui est un substrat de beta-ribosidase en combinaison avec au moins un autre indicateur métabolique et/ou au moins un régulateur métabolique; b) ensemencer le milieu avec un échantillon biologique à tester; c) laisser incuber, et; d) caractériser la présence de Staphylococcus aureus .

Abstract translation: 本发明涉及用于表征葡萄球菌金黄色葡萄球菌的反应介质，其包含与至少另一种代谢指示剂组合的β核糖酶底物和/或至少一种代谢调节剂组成的代谢指示剂。 本发明还涉及用于检测和/或鉴定金黄色葡萄球菌金黄色葡萄球菌的方法，其特征在于其包括以下步骤：a）提供包含由β-核糖酶底物组成的代谢指示剂与至少另一种代谢指示剂组合的反应介质 和/或至少一种代谢调节剂; b）用待测试的生物样品接种培养基; c）允许孵化; 和d）表征金黄色葡萄球菌的存在。

公开(公告)号：WO2009032470A2

公开(公告)日：2009-03-12

申请号：PCT/US2008/072442

申请日：2008-08-07

Applicant: TRUSTEES OF DARTMOUTH COLLEGE ,  CHEUNG, Ambrose ,  MEMMI, Guido

Inventor： CHEUNG, Ambrose ,  MEMMI, Guido

IPC: C12Q1/68

CPC classification number: A61K45/06 ,  A61K31/546 ,  C12Q1/18 ,  C12Q1/689 ,  G01N2333/31 ,  A61K2300/00

Abstract: The present invention includes compositions and methods for diagnosing and treating CA-MRSA infections in patients. The methods are based on the finding that combining cefoxitin and a synthetic penicillin in a treatment regimen results in a synergistic effect of the two drugs, an effect that is related to PBP4 activity in CA-MRSA isolates. Also provided is a CA-MRSA-specif ic biomarker which can be used to detect the presence of a CA-MRSA infection in a patient.

Abstract translation: 本发明包括用于诊断和治疗患者中的CA-MRSA感染的组合物和方法。 该方法基于这样的发现，即在治疗方案中将头孢西丁与合成青霉素相结合导致两种药物的协同效应，这与CA-MRSA分离物中的PBP4活性有关。 还提供了可用于检测患者中CA-MRSA感染的CA-MRSA特异性生物标志物。

公开(公告)号：WO2008026105A2

公开(公告)日：2008-03-06

申请号：PCT/IB2007052872

申请日：2007-07-18

Applicant: KIMBERLY CLARK CO ,  MARTIN STEPHANIE M ,  LONG ANDREW M ,  MACDONALD J GAVIN ,  LYE JASON

Inventor： MARTIN STEPHANIE M ,  LONG ANDREW M ,  MACDONALD J GAVIN ,  LYE JASON

CPC classification number: A61L15/56 ,  G01N2333/245 ,  G01N2333/31 ,  G01N2333/40

Abstract: A method and system for rapidly detecting Candida on the skin of a host, such as an infant with diaper rash, is provided. The method includes contacting a dermal sample with a colorant that exhibits a certain spectral response (e.g., color change) in the presence of Candida. For example, the colorant may change from a first color to a second color, from colorless to a color, or from a color to colorless. The colorant is typically capable of differentiating between Candida (e.g., Candida albicans) and other microorganisms commonly associated with diaper rash, such as S. aureus and E. coli. Thus, when a dermal sample is placed into contact with the colorant, the color change may simply be observed to determine whether the infection is caused by Candida. If the color change occurs to a certain extent (e.g., from yellow to bright red), it may be determined that the test sample contains Candida. Likewise, if a color change occurs to a lesser extent (e.g., from yellow to faint orange) or not at all, it may be determined that the dermal sample contains other microorganisms (e.g., S. aureus or E. coli), no infection is present, or that the infection is simply due to other causes. Regardless, it will become readily apparent whether or not treatment for Candida is needed.

Abstract translation: 提供了用于快速检测宿主皮肤上的假丝酵母的方法和系统，例如具有尿布疹的婴儿。 该方法包括使真皮样品与在假丝酵母存在下显示特定光谱响应（例如颜色变化）的着色剂接触。 例如，着色剂可以从第一颜色变为第二颜色，从无色到颜色，或从颜色变为无色。 着色剂通常能够区分假丝酵母（例如白色念珠菌）和通常与尿布疹相关的其它微生物，例如金黄色葡萄球菌和大肠杆菌。 因此，当真皮样品与着色剂接触时，可以简单地观察颜色变化以确定感染是否由念珠菌引起。 如果颜色变化发生一定程度（例如，从黄色到鲜红色），则可以确定测试样品含有念珠菌。 同样地，如果在较小程度上发生颜色变化（例如，从黄色到微弱的橙色），或根本不发生变色，则可以确定真皮样品含有其他微生物（例如金黄色葡萄球菌或大肠杆菌），无感染 存在，或感染仅仅是由于其他原因。 无论是否需要对念珠菌的治疗，将变得显而易见。

公开(公告)号：WO2008012552A1

公开(公告)日：2008-01-31

申请号：PCT/GB2007/002856

申请日：2007-07-26

Applicant: ISIS INNOVATION LIMITED ,  DUKE UNIVERSITY ,  BAYLEY, John Hagan Pryce ,  HOLDEN, Matthew ,  HERON, Andrew John ,  NEEDHAM, David

Inventor： BAYLEY, John Hagan Pryce ,  HOLDEN, Matthew ,  HERON, Andrew John ,  NEEDHAM, David

IPC: G01N33/543 ,  G01N33/68

CPC classification number: G01N33/6872 ,  G01N33/5432 ,  G01N2333/31 ,  Y10T436/12

Abstract: A method of forming bilayers of amphipathic molecules uses droplets of aqueous solution in a hydrophobic medium such as oil. A layer of amphipathic molecules such as a lipid is formed around the surfaces of the droplets. This may be achieved by providing the lipid in the oil and leaving the droplets for a time sufficient to form the layer. The droplets are brought into contact with one another so that a bilayer of the amphipathic molecules is formed as an interface between the contacting droplets. The bilayers may be used for a wide range of studies. The technique has numerous advantages including providing a long lifetime for the bilayers, allowing study of small volumes and allowing the construction of chains and networks of droplets with bilayers in between to study complex systems.

Abstract translation: 形成两亲分子双层的方法使用疏水介质如油中的水溶液滴。 在液滴的表面周围形成一层两亲性分子，例如脂质。 这可以通过在油中提供脂质并将液滴留下足以形成该层的时间来实现。 使液滴彼此接触，使得两亲分子的双层形成为接触液滴之间的界面。 双层可用于广泛的研究。 该技术具有许多优点，包括为双层提供长寿命，允许研究小体积，并允许在双层之间建立具有双层的液滴链和网络以研究复杂系统。

公开(公告)号：WO2007024852A3

公开(公告)日：2007-06-28

申请号：PCT/US2006032764

申请日：2006-08-22

Applicant: BIOSYNEXUS INC ,  KOKAI-KUN JOHN FITZGERALD ,  MOND JAMES JACOB

Inventor： KOKAI-KUN JOHN FITZGERALD ,  MOND JAMES JACOB

IPC: H04Q7/20

CPC classification number: A61K39/085 ,  A61K49/0008 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/543 ,  G01N2333/31

Abstract: Methods and a rodent model to test the effectiveness of vaccine candidates against bacteria, e.g., Staphylococcus aureus by systemically immunizing a rodent, particularly a cotton rat, with a vaccine candidate, intranasally challenging the cotton rat with the selected bacteria, and detecting a response with respect to an immune response, nasal colonization as a measure of the protective effect of the vaccine candidate, or both.

Abstract translation: 通过用候选疫苗对啮齿类动物，特别是棉鼠进行系统免疫，用选定的细菌对棉鼠进行鼻内攻击，以及使用所选择的细菌对棉鼠进行鼻内攻击来测试针对细菌例如金黄色葡萄球菌的疫苗候选物的有效性的方法和啮齿动物模型， 尊重免疫应答，作为疫苗候选物保护作用的量度的鼻定植，或两者。

公开(公告)号：WO2006070416A1

公开(公告)日：2006-07-06

申请号：PCT/IT2004/000738

申请日：2004-12-30

Applicant: FONDAZIONE SANTA LUCIA I.R.C.C.S. ,  TILMANN, Achsel

Inventor： TILMANN, Achsel

IPC: G01N33/531 ,  C12N15/62

CPC classification number: G01N33/531 ,  C07K1/22 ,  G01N33/6854 ,  G01N2333/31

Abstract: This invention concerns an artificial adapter protein that combines an antibody-binding activity with two affinity tags and its use in isolation of antibody-antigen complexes. Using this adapter protein, complexes can be obtained at good yield and in the high purity necessary for the identification of all biological macromolecules that are associated with the antigen.

Abstract translation: 本发明涉及将抗体结合活性与两种亲和标签结合的人工衔接蛋白及其在分离抗体 - 抗原复合物中的用途。 使用这种衔接蛋白，可以以良好的产率和高纯度获得复合物，用于鉴定与抗原相关的所有生物大分子。